{"transactions":[{"id":833871,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-03-19T20:50:54.000Z","date":"2026-03-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":1693,"price":56.05,"value":94892.65,"ownership":{"direct":true},"balance_after":84140,"source":{"system":"sec-edgar","filing":"0001628280-26-019857","document":"wk-form4_1773953452.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000162828026019857/wk-form4_1773953452.xml","form_type":"4"}},{"id":839165,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Stock Option (Right to Buy Common Stock)","published_at":"2026-03-18T00:50:38.000Z","date":"2026-03-16","kind":"grant","planned":false,"acquired":true,"shares":35680,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option grant vests 12/48th on March 16, 2027 and 1/48th on the 16th day of each month thereafter."}],"balance_after":35680,"derivative":{"exercise_price":57.43,"exercise_date":"2027-03-16","expiration_date":"2036-03-15","underlying":"Common Stock","underlying_shares":35680},"source":{"system":"sec-edgar","filing":"0001628280-26-019012","document":"wk-form4_1773795035.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000162828026019012/wk-form4_1773795035.xml","form_type":"4"}},{"id":839164,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-03-18T00:50:38.000Z","date":"2026-03-16","kind":"grant","planned":false,"acquired":true,"shares":14990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted March 16, 2026. Price not applicable."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person's direct holdings have been adjusted by one share to correct a previous clerical error."}],"balance_after":85833,"source":{"system":"sec-edgar","filing":"0001628280-26-019012","document":"wk-form4_1773795035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000162828026019012/wk-form4_1773795035.xml","form_type":"4"}},{"id":839163,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-03-18T00:50:38.000Z","date":"2026-03-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":9109,"price":58.51,"value":532967.59,"ownership":{"direct":true},"balance_after":70843,"source":{"system":"sec-edgar","filing":"0001628280-26-019012","document":"wk-form4_1773795035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000162828026019012/wk-form4_1773795035.xml","form_type":"4"}},{"id":846880,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-03-12T23:55:45.000Z","date":"2026-03-11","kind":"sale","planned":false,"acquired":false,"shares":16486,"price":60.46,"value":996743.56,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is the weighted average price. The purchase price actually received ranged from $60.39 to $60.62. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price"}],"balance_after":79953,"source":{"system":"sec-edgar","filing":"0001628280-26-017447","document":"wk-form4_1773359742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000162828026017447/wk-form4_1773359742.xml","form_type":"4"}},{"id":880228,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-02-27T01:49:52.000Z","date":"2026-02-25","kind":"grant","planned":false,"acquired":true,"shares":2371,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events."},{"field":"shares","element":"transactionShares","label":"F5","text":"Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan."}],"balance_after":96439,"source":{"system":"sec-edgar","filing":"0001628280-26-012542","document":"wk-form4_1772156989.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000162828026012542/wk-form4_1772156989.xml","form_type":"4"}},{"id":880227,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-02-27T01:49:52.000Z","date":"2026-02-25","kind":"grant","planned":false,"acquired":true,"shares":6675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan."}],"balance_after":94068,"source":{"system":"sec-edgar","filing":"0001628280-26-012542","document":"wk-form4_1772156989.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000162828026012542/wk-form4_1772156989.xml","form_type":"4"}},{"id":880226,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-02-27T01:49:52.000Z","date":"2026-02-25","kind":"grant","planned":false,"acquired":true,"shares":6176,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events."}],"balance_after":87393,"source":{"system":"sec-edgar","filing":"0001628280-26-012542","document":"wk-form4_1772156989.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000162828026012542/wk-form4_1772156989.xml","form_type":"4"}},{"id":905770,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-02-13T23:56:35.000Z","date":"2025-10-31","kind":"grant","planned":false,"acquired":true,"shares":62,"price":45.535,"value":2823.17,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"Represents the shares acquired by the reporting person on October 31, 2025, pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":81217,"source":{"system":"sec-edgar","filing":"0001628280-26-008221","document":"wk-form5_1771026992.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000162828026008221/wk-form5_1771026992.xml","form_type":"5"}},{"id":905769,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-02-13T23:56:35.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":317,"price":54.137,"value":17161.429,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents the shares acquired by the reporting person on April 30, 2025, pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":81155,"source":{"system":"sec-edgar","filing":"0001628280-26-008221","document":"wk-form5_1771026992.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000162828026008221/wk-form5_1771026992.xml","form_type":"5"}},{"id":1201342,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Stock Option (Right to Buy Common Stock)","published_at":"2025-03-18T22:22:00.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":30880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option grant vests 12/48th on March 17, 2026 and 1/48th on the 17th day of each month thereafter."}],"balance_after":30880,"derivative":{"exercise_price":71.55,"exercise_date":"2026-03-17","expiration_date":"2035-03-16","underlying":"Common Stock","underlying_shares":30880},"source":{"system":"sec-edgar","filing":"0001048477-25-000031","document":"wk-form4_1742336512.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000031/wk-form4_1742336512.xml","form_type":"4"}},{"id":1201341,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-03-18T22:22:00.000Z","date":"2025-03-17","kind":"grant","planned":false,"acquired":true,"shares":13310,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted March 17, 2025. Price not applicable."}],"balance_after":80838,"source":{"system":"sec-edgar","filing":"0001048477-25-000031","document":"wk-form4_1742336512.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000031/wk-form4_1742336512.xml","form_type":"4"}},{"id":1201340,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-03-18T22:22:00.000Z","date":"2025-03-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":20127,"price":69.44,"value":1397618.88,"ownership":{"direct":true},"balance_after":67528,"source":{"system":"sec-edgar","filing":"0001048477-25-000031","document":"wk-form4_1742336512.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000031/wk-form4_1742336512.xml","form_type":"4"}},{"id":1218104,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-03-07T21:06:24.000Z","date":"2025-03-06","kind":"sale","planned":false,"acquired":false,"shares":7034,"price":71.276,"value":501355.384,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is the weighted average price. The price actually received ranged from $71.276 to $71.285. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price."}],"balance_after":87655,"source":{"system":"sec-edgar","filing":"0001048477-25-000025","document":"wk-form4_1741381578.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000025/wk-form4_1741381578.xml","form_type":"4"}},{"id":1231045,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-03-04T21:11:20.000Z","date":"2025-02-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":4287,"price":71.16,"value":305062.92,"ownership":{"direct":true},"balance_after":94689,"source":{"system":"sec-edgar","filing":"0001048477-25-000021","document":"wk-form4_1741122664.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000021/wk-form4_1741122664.xml","form_type":"4"}},{"id":1241452,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-02-28T00:17:26.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":9367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2025, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events."},{"field":"shares","element":"transactionShares","label":"F5","text":"Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan."}],"balance_after":98976,"source":{"system":"sec-edgar","filing":"0001048477-25-000017","document":"wk-form4_1740701840.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000017/wk-form4_1740701840.xml","form_type":"4"}},{"id":1241451,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-02-28T00:17:26.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":9660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2025, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan."}],"balance_after":89609,"source":{"system":"sec-edgar","filing":"0001048477-25-000017","document":"wk-form4_1740701840.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000017/wk-form4_1740701840.xml","form_type":"4"}},{"id":1241450,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-02-28T00:17:26.000Z","date":"2025-02-25","kind":"grant","planned":false,"acquired":true,"shares":11040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2025, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events."}],"balance_after":79949,"source":{"system":"sec-edgar","filing":"0001048477-25-000017","document":"wk-form4_1740701840.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000017/wk-form4_1740701840.xml","form_type":"4"}},{"id":1365486,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-11-14T19:44:40.000Z","date":"2024-11-12","kind":"sale","planned":false,"acquired":false,"shares":5278,"price":66.3743,"value":350323.5554,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is the weighted average price. The purchase price actually received ranged from $66.37 to $66.395. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price."}],"balance_after":68909,"source":{"system":"sec-edgar","filing":"0001048477-24-000154","document":"wk-form4_1731613473.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000154/wk-form4_1731613473.xml","form_type":"4"}},{"id":1365485,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-11-14T19:44:40.000Z","date":"2024-10-31","kind":"grant","planned":false,"acquired":true,"shares":55,"price":56.007,"value":3080.385,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents the shares acquired by the reporting person on October 31, 2024, pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":74187,"source":{"system":"sec-edgar","filing":"0001048477-24-000154","document":"wk-form4_1731613473.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000154/wk-form4_1731613473.xml","form_type":"4"}},{"id":1525080,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-05-07T21:58:28.000Z","date":"2024-05-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":4440,"price":82.44,"value":366033.6,"ownership":{"direct":true},"balance_after":74132,"source":{"system":"sec-edgar","filing":"0001048477-24-000077","document":"wk-form4_1715119099.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000077/wk-form4_1715119099.xml","form_type":"4"}},{"id":1525079,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-05-07T21:58:28.000Z","date":"2024-04-30","kind":"grant","planned":false,"acquired":true,"shares":245,"price":68.646,"value":16818.27,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":78572,"source":{"system":"sec-edgar","filing":"0001048477-24-000077","document":"wk-form4_1715119099.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000077/wk-form4_1715119099.xml","form_type":"4"}},{"id":1570145,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Stock Option (Right to Buy Common Stock)","published_at":"2024-03-20T00:50:49.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":23630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option grant vests 12/48th on March 15, 2025 and 1/48th on the 15th day of each month thereafter."}],"balance_after":23630,"derivative":{"exercise_price":83.87,"exercise_date":"2025-03-15","expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":23630},"source":{"system":"sec-edgar","filing":"0001048477-24-000046","document":"wk-form4_1710895840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000046/wk-form4_1710895840.xml","form_type":"4"}},{"id":1570144,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-03-20T00:50:49.000Z","date":"2024-03-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":20424,"price":83.87,"value":1712960.88,"ownership":{"direct":true},"balance_after":78327,"source":{"system":"sec-edgar","filing":"0001048477-24-000046","document":"wk-form4_1710895840.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000046/wk-form4_1710895840.xml","form_type":"4"}},{"id":1570143,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-03-20T00:50:49.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":10550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted March 15, 2024. Price not applicable."}],"balance_after":98751,"source":{"system":"sec-edgar","filing":"0001048477-24-000046","document":"wk-form4_1710895840.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000046/wk-form4_1710895840.xml","form_type":"4"}},{"id":1610640,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-02-29T22:14:19.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":6284,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events."},{"field":"shares","element":"transactionShares","label":"F5","text":"Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan."}],"balance_after":88201,"source":{"system":"sec-edgar","filing":"0001048477-24-000024","document":"wk-form4_1709244839.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000024/wk-form4_1709244839.xml","form_type":"4"}},{"id":1610639,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-02-29T22:14:19.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":9063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan."}],"balance_after":81917,"source":{"system":"sec-edgar","filing":"0001048477-24-000024","document":"wk-form4_1709244839.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000024/wk-form4_1709244839.xml","form_type":"4"}},{"id":1610638,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-02-29T22:14:19.000Z","date":"2024-02-27","kind":"grant","planned":false,"acquired":true,"shares":20840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F3","text":"Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events."}],"balance_after":72854,"source":{"system":"sec-edgar","filing":"0001048477-24-000024","document":"wk-form4_1709244839.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000024/wk-form4_1709244839.xml","form_type":"4"}},{"id":1722386,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-12-05T21:59:08.000Z","date":"2023-12-01","kind":"grant","planned":false,"acquired":true,"shares":11840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Restricted stock units granted on December 1, 2023. Price not applicable."}],"balance_after":52014,"source":{"system":"sec-edgar","filing":"0001048477-23-000051","document":"wk-form4_1701813536.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847723000051/wk-form4_1701813536.xml","form_type":"4"}},{"id":1722385,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-12-05T21:59:08.000Z","date":"2023-10-31","kind":"grant","planned":false,"acquired":true,"shares":133,"price":69.233,"value":9207.989,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents the shares acquired by the reporting person on October 31, 2023, pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":40174,"source":{"system":"sec-edgar","filing":"0001048477-23-000051","document":"wk-form4_1701813536.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847723000051/wk-form4_1701813536.xml","form_type":"4"}},{"id":1811112,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-08-10T20:47:58.000Z","date":"2023-08-09","kind":"sale","planned":false,"acquired":false,"shares":5360,"price":93.304,"value":500109.44,"ownership":{"direct":true},"balance_after":40041,"source":{"system":"sec-edgar","filing":"0001048477-23-000035","document":"wk-form4_1691700467.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847723000035/wk-form4_1691700467.xml","form_type":"4"}},{"id":1901245,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-05-08T20:20:57.000Z","date":"2023-05-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":4302,"price":95.45,"value":410625.9,"ownership":{"direct":true},"balance_after":45401,"source":{"system":"sec-edgar","filing":"0001209191-23-027934","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000120919123027934/doc4.xml","form_type":"4"}},{"id":1901244,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-05-08T20:20:57.000Z","date":"2023-04-28","kind":"grant","planned":false,"acquired":true,"shares":239,"price":66.88,"value":15984.32,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents the shares acquired by the reporting person on April 28, 2023, pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":49703,"source":{"system":"sec-edgar","filing":"0001209191-23-027934","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000120919123027934/doc4.xml","form_type":"4"}},{"id":1948016,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2023-03-18T01:47:15.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":20320,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option grant vests 12/48th on March 15, 2024 and 1/48th on the 15th day of each month thereafter."}],"balance_after":20320,"derivative":{"exercise_price":87.74,"exercise_date":"2024-03-15","expiration_date":"2033-03-14","underlying":"Common Stock","underlying_shares":20320},"source":{"system":"sec-edgar","filing":"0001567619-23-005299","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761923005299/doc1.xml","form_type":"4"}},{"id":1948015,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-03-18T01:47:15.000Z","date":"2023-03-15","kind":"tax_withholding","acquired":false,"shares":1856,"price":87.74,"value":162845.44,"ownership":{"direct":true},"balance_after":49464,"source":{"system":"sec-edgar","filing":"0001567619-23-005299","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761923005299/doc1.xml","form_type":"4"}},{"id":1948014,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-03-18T01:47:15.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":8900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on March 15, 2023. Price not applicable."}],"balance_after":51320,"source":{"system":"sec-edgar","filing":"0001567619-23-005299","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761923005299/doc1.xml","form_type":"4"}},{"id":2023282,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-02-11T02:57:09.000Z","date":"2022-10-31","kind":"grant","acquired":true,"shares":252,"price":62.407,"value":15726.564,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired by the reporting person on October 31, 2022, pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":42420,"source":{"system":"sec-edgar","filing":"0001567619-23-002422","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761923002422/doc1.xml","form_type":"5"}},{"id":2189885,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2022-08-10T23:52:23.000Z","date":"2022-08-08","kind":"sale","acquired":false,"shares":6205,"price":96.56,"value":599154.8,"ownership":{"direct":true},"balance_after":42168,"source":{"system":"sec-edgar","filing":"0001567619-22-015499","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922015499/doc1.xml","form_type":"4"}},{"id":2279633,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2022-05-07T00:19:02.000Z","date":"2022-05-04","kind":"tax_withholding","acquired":false,"shares":3926,"price":84.65,"value":332335.9,"ownership":{"direct":true},"balance_after":48373,"source":{"system":"sec-edgar","filing":"0001567619-22-009719","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922009719/doc1.xml","form_type":"4"}},{"id":2279632,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2022-05-07T00:19:02.000Z","date":"2022-04-29","kind":"grant","acquired":true,"shares":243,"price":62.407,"value":15164.901,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired by the reporting person on April 29, 2022, pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":52299,"source":{"system":"sec-edgar","filing":"0001567619-22-009719","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922009719/doc1.xml","form_type":"4"}},{"id":2328541,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2022-03-18T01:30:44.000Z","date":"2022-03-15","kind":"grant","acquired":true,"shares":26520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option grant vests 12/48th on March 15, 2023 and 1/48th on the 15th day of each month thereafter."}],"balance_after":26520,"derivative":{"exercise_price":78.27,"exercise_date":"2023-03-15","expiration_date":"2032-03-14","underlying":"Common Stock","underlying_shares":26520},"source":{"system":"sec-edgar","filing":"0001567619-22-007183","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922007183/doc1.xml","form_type":"4"}},{"id":2328540,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2022-03-18T01:30:44.000Z","date":"2022-03-15","kind":"tax_withholding","acquired":false,"shares":920,"price":78.27,"value":72008.4,"ownership":{"direct":true},"balance_after":52056,"source":{"system":"sec-edgar","filing":"0001567619-22-007183","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922007183/doc1.xml","form_type":"4"}},{"id":2328539,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2022-03-18T01:30:44.000Z","date":"2022-03-15","kind":"grant","acquired":true,"shares":11040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on March 15, 2022. Price not applicable."}],"balance_after":52976,"source":{"system":"sec-edgar","filing":"0001567619-22-007183","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922007183/doc1.xml","form_type":"4"}},{"id":2402332,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2022-02-12T02:51:34.000Z","date":"2021-10-29","kind":"grant","acquired":true,"shares":241,"price":62.407,"value":15040.087,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired by the reporting person on October 29, 2021, pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":41936,"source":{"system":"sec-edgar","filing":"0001567619-22-003787","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922003787/doc1.xml","form_type":"5"}},{"id":2727897,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2021-05-06T00:46:36.000Z","date":"2021-05-04","kind":"tax_withholding","acquired":false,"shares":3986,"price":78.35,"value":312303.1,"ownership":{"direct":true},"balance_after":41695,"source":{"system":"sec-edgar","filing":"0001567619-21-009154","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761921009154/doc1.xml","form_type":"4"}},{"id":2727896,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2021-05-06T00:46:36.000Z","date":"2021-04-30","kind":"grant","acquired":true,"shares":221,"price":62.407,"value":13791.947,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired by the reporting person on April 30, 2021, pursuant to the issuer's Employee Stock Purchase Plan."}],"balance_after":45681,"source":{"system":"sec-edgar","filing":"0001567619-21-009154","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761921009154/doc1.xml","form_type":"4"}},{"id":2783482,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2021-03-18T01:42:59.000Z","date":"2021-03-15","kind":"grant","acquired":true,"shares":25650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"Option grant vests 12/48th on March 15, 2022 and 1/48th on the 15th day of each month thereafter."}],"balance_after":25650,"derivative":{"exercise_price":78.39,"exercise_date":"2022-03-15","expiration_date":"2031-03-14","underlying":"Common Stock","underlying_shares":25650},"source":{"system":"sec-edgar","filing":"0001567619-21-006557","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761921006557/doc1.xml","form_type":"4"}},{"id":2783481,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2021-03-18T01:42:59.000Z","date":"2021-03-15","kind":"grant","acquired":true,"shares":10420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on March 15, 2021.  Price not applicable."}],"balance_after":45460,"source":{"system":"sec-edgar","filing":"0001567619-21-006557","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761921006557/doc1.xml","form_type":"4"}},{"id":3159899,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Stock Option (Right to buy Common Stock)","published_at":"2020-05-07T00:10:28.000Z","date":"2020-05-04","kind":"grant","acquired":true,"shares":64150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"Option grant vests 12/48th on May 4, 2021 and 1/48th on the 4th day of each month thereafter."}],"balance_after":64150,"derivative":{"exercise_price":90.36,"exercise_date":"2021-05-04","expiration_date":"2030-05-03","underlying":"Common Stock","underlying_shares":64150},"source":{"system":"sec-edgar","filing":"0001567619-20-009172","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920009172/doc1.xml","form_type":"4"}},{"id":3159898,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":57237,"kind":"person","name":"Guyer Charles Greg","position":1,"cik":"0001811096","reported_name":"Guyer Charles Greg","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2020-05-07T00:10:28.000Z","date":"2020-05-04","kind":"grant","acquired":true,"shares":35040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on May 4, 2020. Price not applicable."}],"balance_after":35040,"source":{"system":"sec-edgar","filing":"0001567619-20-009172","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920009172/doc1.xml","form_type":"4"}}]}